André J. Müller
Directeur/Bestuurslid bij Anokion SA
Oorsprong van het eerstegraads netwerk van André J. Müller
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 23 | |
13
| Extinct | Pharmaceuticals: Major | 13 |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.
13
| Holding Company | Medical/Nursing Services | 13 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met André J. Müller via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chairman | |
| NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal Corporate Officer/Principal | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
| École Polytechnique Fédérale de Lausanne | College/University | Corporate Officer/Principal Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Vermont | College/University | Doctorate Degree Doctorate Degree | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Private Equity Investor | |
| University of Geneva | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| University of Bern | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| ESSEC Business School | College/University | Masters Business Admin Masters Business Admin | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder Founder Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Founder Director/Board Member | |
| Euro Ventures, Inc. | Founder | ||
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman | |
Actelion Pharmaceuticals Korea Ltd.
 Actelion Pharmaceuticals Korea Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Korea Ltd. is a South Korean pharmaceutical company that manufactures pharmaceutical products. The company is based in Seoul, South Korea. The company was founded in 1983. The CEO is Jenny Jeong. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director of Finance/CFO Director/Board Member | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Chairman | |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Versant Venture Capital VI (Canada) LP
 Versant Venture Capital VI (Canada) LP Investment ManagersFinance Versant Venture Capital VI (Canada) LP operates as a pooled investment fund. The company is headquartered in San Francisco, CA. | Investment Managers | Director/Board Member | |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman | |
| IDORSIA LTD | Pharmaceuticals: Major | Chief Executive Officer General Counsel Human Resources Officer | |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CAPTOR THERAPEUTICS SPOLKA AKCYJNA | Pharmaceuticals: Major | Director/Board Member | |
Jengu Therapeutics, Inc.
 Jengu Therapeutics, Inc. BiotechnologyHealth Technology Jengu Therapeutics, Inc. is a biotechnology company. The company is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer Founder | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Chairman | |
| Okarios AG | Chief Operating Officer | ||
| Swissvention Partners GmbH | Chief Executive Officer | ||
| TEMPEST THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 20 |
| Zwitserland | 16 |
| Frankrijk | 5 |
| Verenigd Koninkrijk | 4 |
| Ierland | 3 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 10 |
| Finance | 3 |
| Commercial Services | 3 |
| Technology Services | 2 |
Operationeel
| Director/Board Member | 270 |
| Corporate Officer/Principal | 113 |
| Chairman | 49 |
| Independent Dir/Board Member | 46 |
| Founder | 38 |
Sterkste connecties
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Thomas Woiwode | 39 |
| Ho Young Huh | 32 |
| Florent Gros | 28 |
| Nilesh Kumar | 26 |
| Beat E. Lüthi | 24 |
| Bharatt Chowrira | 24 |
| Ray Hill | 18 |
| Graham Dixon | 18 |
| Oleg Nodelman | 15 |
| Patricia Allen | 14 |
| Alexandra Goll | 14 |
| Michael Clayman | 13 |
| Otto Schwarz | 13 |
| Simon Buckingham | 13 |
- Beurs
- Insiders
- André J. Müller
- Bedrijfsconnecties
